Reversal of Cognitive Decline: 100 Patients

Dale E Bredesen1, Kenneth Sharlin2, David Jenkins3, Miki Okuno4, Wes Youngberg1, Sharon Hausman Cohen3, Anne Stefani2, Ronald L Brown5, Seth Conger6, Craig Tanio7, Ann Hathaway8, Mikhail Kogan9, David Hagedorn10, Edwin Amos11, Amylee Amos12, Nathaniel Bergman13, Carol Diamond14, Jean Lawrence15, Ilene Naomi Rusk16, Patricia Henry16 and Mary Braud16

1Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA
2Sharlin Health and Neurology/Functional Medicine, Ozark, MO, USA
3NeuroHub, Sydney, Australia
4Youngberg Lifestyle Medicine Clinic, Temecula, CA, USA
5Resilient Health, Austin, TX, USA
6Carolina Healthspan Institute, Charlotte, NC, USA
7Rezilir Health, Hollywood, FL, USA
8Integrative Functional Medicine, San Rafael, CA, USA
9GW Center for Integrative Medicine, George Washington University, Washington, DC, USA
10Coastal Integrative Medicine, Jacksonville, NC, USA
11Department of Neurology, University of California, Los Angeles, Los Angeles, CA, USA
12Amos Institute, Los Angeles, CA, USA
13Center for Functional Medicine, Cleveland Clinic, Cleveland, OH, USA
14Mount Sinai Hospital, New York, NY, USA
15Lawrence Health and Wellness, Toccoa, GA, USA
16Brain and Behavior Clinic, Boulder, CO, USA

Abstract

The first examples of reversal of cognitive decline in Alzheimer’s disease and the pre-Alzheimer’s disease conditions MCI (Mild Cognitive Impairment) and SCI (Subjective Cognitive Impairment) have recently been published. These two publications described a total of 19 patients showing sustained subjective and objective improvement in cognition, using a comprehensive, precision medicine approach that involves determining the potential contributors to the cognitive decline (e.g., activation of the innate immune system by pathogens or intestinal permeability, reduction in trophic or hormonal support, specific toxin exposure, or other contributors), using a computer-based algorithm to determine subtype and then addressing each contributor using a personalized, targeted, multi-factorial approach dubbed ReCODE for reversal of cognitive decline.

An obvious criticism of the initial studies is the small number of patients reported. Therefore, we report here 100 patients, treated by several different physicians, with documented improvement in cognition, in some cases with documentation of improvement in electrophysiology or imaging, as well. This additional report provides further support for a randomized, controlled clinical trial of the protocol and the overall approach.

Keywords: Alzheimer’s; Mild cognitive impairment; Programmatics; ReCODE; Precision medicine; Amyloid precursor protein; Synaptoblastic; Synaptoclastic

Introduction

Alzheimer’s disease is now the third leading cause of death in the United States [1-6], and the development of effective treatment and prevention is a major healthcare goal. However, clinical trials of drug candidates for Alzheimer’s disease treatment have been almost uniformly unsuccessful. There may be several reasons for such repeated failure: (1) given the long pre-symptomatic period, treatment is typically initiated late in the pathophysiological process; (2) what is referred to as Alzheimer’s disease is not a single disease, but rather exhibits several different subtypes [3,4]; (3) just as for other complex chronic illnesses such as cardiovascular disease, there may be many potential contributors to Alzheimer’s disease, such as inflammation, various chronic pathogens, trophic withdrawal, insulin resistance, vascular compromise, trauma, and exposure to specific toxins. Therefore, a monotherapeutic, monophasic approach is likely to be suboptimal, and personalized, multiphasic programs based on each individual’s genetics and biochemistry may be preferable. Indeed, such personalized programs may offer advantages in future clinical trials of drug candidates. (4) The model of Alzheimer’s disease on which the drug targets (e.g., amyloid-β peptide) have been based may be an inaccurate or incomplete model of the disease.

We have argued for a fundamentally different view of Alzheimer’s disease [1,2,5,7] in which APP, the amyloid precursor protein, functions as a molecular switch due to its activity as an integrating dependence receptor [8-10]: in the presence of sufficient support from trophic signaling, APP is cleaved at the alpha site, leading to the production of two synaptoclastic peptides, sAPPβ and Aβ. In contrast, in the absence of sufficient support from trophic signaling, APP is cleaved at the beta, gamma, and caspase sites, leading to the production of four synaptoclastic peptides, sAPPβ, Aβ, Jcasp, and C31. In this model, inflammation exerts an anti-trophic effect on APP signaling, at least in part via the NF-κB (nuclear factor k-light chain enhancer of B cells) induction of BACE (beta-amyloid cleaving enzyme) and gamma-secretase activity. Similarly, toxins such as divalent metals (e.g., mercury) also exert an anti-trophic effect on APP signaling, since these lead to a net increased production of the toxin-binding peptide, Aβ. This
model is compatible with the finding that the Aβ peptide functions as an antimicrobial peptide [11], together suggesting that what is referred to as Alzheimer's disease is a protective, network-downsizing response to several classes of insults: pathogens/inflammation, toxins, and withdrawal of nutrients, hormones, or trophic factors [5].

This model suggests that the probability of developing Alzheimer's disease is proportional to the ratio of synaptoclastic signaling to synaptoblastic signaling [5]. This notion has led to a treatment regimen in which the dozens of contributors to synaptoblastic and synaptoclastic signaling are measured for each patient, and a personalized program is generated to target each contributor, thus increasing synaptoblastic signals and reducing identified synaptoclastic signals. Some examples include: (1) identifying and treating pathogens such as Borrelia, Babesia, or Herpes family viruses; (2) identifying gastrointestinal hyperpermeability, repairing the gut, and enhancing the microbiome; (3) identifying insulin resistance and protein glycation, and returning insulin sensitivity and reduced protein glycation; (4) identifying and correcting suboptimal nutrient, hormone, or trophic support (including vascular support); (5) identifying toxins (metalloxidogens and other inorganics, organic toxins, or biotoxins), reducing toxin exposure, and detoxifying. Since each patient has a different combination of the many potential contributors to cognitive decline, the approach to treatment is targeted and personalized.

Here we describe 100 patients with cognitive decline treated with this multi-component, precision medicine approach, and showing documented improvement.

Case Studies

Patient 1

A 68-year-old professional woman began to note paraphasic errors in her speech, severe enough that it created confusion in her listeners. She also developed depression, and was treated with an antidepressant. She began to have difficulty with everyday work such as shopping, cooking, and working at the computer. She struggled to complete a gingerbread man with her granddaughter, even though she had done this without difficulty many times before. She confused the minute hand and hour hand on a clock. She had difficulty with spelling. Her symptoms progressed, and she began to forget daily tasks. She struggled to complete a meal, paying bills, navigating, even difficulty finding her way back to her restaurant table after using the restroom.

She was found to be heterozygous for the ε4 allele of apolipoprotein E (ApoE 3/4). An amyloid PET scan (flortbetapir) was positive. MRI twice in a two-week period. She was very concerned when she forgot to pick up her grandchildren at school twice in a two-week period. She began to have difficulty with everyday work such as shopping, cooking, and working at the computer. She struggled to complete a meal, paying bills, navigating, even difficulty finding her way back to her restaurant table after using the restroom.

Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) scan revealed a decrease in glucose utilization in the anterior superior temporal lobe. MRI revealed mild biparietal atrophy, with decreased hippocampal volume (16th percentile for age). On-line cognitive testing placed her at the 9th percentile for her age. ApoE genotype was 3/3, fasting glucose 90 mg/dL, hemoglobin A1c 5.3%, fasting insulin 1.6 mIU/L, homocysteine 14.1 micromolar, TSH 4.1 mIU/mL, free T3 2.6 pg/mL, reverse T3 22.6 ng/dL, vitamin B12 202 pg/mL, vitamin D 27.4 ng/mL, total cholesterol 226 mg/dL, LDL 121 mg/dL, HDL 92 mg/dL, and mercury 7 ng/mL.

She was treated with the programmatic approach described previously [1], and over 12 months, her on-line cognitive assessment improved from the 9th percentile to the 97th percentile. Her significant other noted that her memory had improved from "disastrous" to "just plain lousy" and finally to "normal." She remains on the therapeutic program, and has sustained her improvement.

Patient 2

A 73-year-old female physician presented with a history of memory decline and word-finding problems that had begun insidiously nearly 20 years previously, but had accelerated over the past year, leading her significant other to describe her memory as "disastrous." She could not remember recent conversations, plays she had seen, or books she had read, and mixed up the names of people and pets. She had trouble navigating, even difficulty finding her way back to her restaurant table after using the restroom.

Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) scan revealed a decrease in glucose utilization in the anterior superior temporal lobe. MRI revealed mild biparietal atrophy, with decreased hippocampal volume (16th percentile for age). On-line cognitive testing placed her at the 9th percentile for her age. ApoE genotype was 3/3, fasting glucose 90 mg/dL, hemoglobin A1c 5.3%, fasting insulin 1.6 mIU/L, homocysteine 14.1 micromolar, TSH 4.1 mIU/mL, free T3 2.6 pg/mL, reverse T3 22.6 ng/dL, vitamin B12 202 pg/mL, vitamin D 27.4 ng/mL, total cholesterol 226 mg/dL, LDL 121 mg/dL, HDL 92 mg/dL, and mercury 7 ng/mL.

She was treated with the programmatic approach described previously [1], and over 12 months, her on-line cognitive assessment improved from the 9th percentile to the 97th percentile. Her significant other noted that her memory had improved from "disastrous" to "just plain lousy" and finally to "normal." She remains on the therapeutic program, and has sustained her improvement.

Patient 3

A 62-year-old woman presented with cognitive decline, fatigue, poor sleep, and depression. She had lost the ability to remember names, do the accounting she had done previously, and run her business.

Body mass index was 24, with increased abdominal fat. MoCA was 20. She was ApoE4 heterozygous (3/4). Fasting serum glucose 101 mg/dL, hemoglobin A1c 6.1%, fasting insulin 14 mg/dL, hs-CRP 1.7 mg/L, 25-hydroxycholecalciferol 24 ng/mL, TSH 2.4 mIU/mL, free T3 2.9 pg/mL, reverse T3 19 ng/dL, estradiol-6 pg/mL, and pregnenolone 38 ng/dL. Pathogen testing was negative for Borrelia, other tick-borne infections, and Herpes family viruses. Toxin testing showed no evidence of mercury or lead toxicity.

She was treated with the personalized program described previously [1], which in her case included bio-identical hormone replacement, restoring insulin sensitivity with a mildly ketogenic, plant-rich diet, regular exercise, and stress reduction; enhancing her microbiome with probiotics and prebiotics; reducing systemic inflammation with omega-3 fats; enhancing vitamin D and vitamin K2; enhancing methylation with methyl-cobalamin and methyl-tetrahydrofolate; and brain training.

Over the next 12 months she improved her metabolic status: her BMI dropped to 21.8, fasting glucose 87 mg/dL, hemoglobin A1c 5.2%, fasting insulin 5.5 mg/dL, hs-CRP 0.5 mg/L, free T3 3.2 pg/mL, TSH 2.1 mIU/L, estradiol 51 pg/mL. Her symptoms resolved, she was able to reopen her business, and her follow-up MoCA score had risen from 20 to 28. Her improvement has been sustained.
(Table 1) lists 100 patients with cognitive decline due to Alzheimer's disease, pre-Alzheimer's conditions MCI (Mild Cognitive Impairment) or SCI (Subjective Cognitive Impairment), or cognitive decline without definitive diagnosis, all of whom demonstrated documented improvement using the same targeted, multi-component program used for the three patients described above.

| Patient | ApoE | Sx | Dx | Evaluation | F/u | Comment |
|---------|------|----|----|------------|-----|---------|
| 1) 68F  | 3/4  | Exec, calc | MCI | Am-PET+ | MoCA 24→30 | Patient 1 (above) |
| 2) 73F  | 3/3  | Amnestic | MCI | FDG-PET+ | 9→97%ile on-line | Patient 2 (above) |
| 3) 59F  | 3/4  | Exec | AD | HC vol <1%ile | MoCA 14→21 |
| 4) 62F  | ND   | Multi-domain | AD | CSF ATI+ | MoCA 9→17 | Returned to work |
| 5) 75F  | 4/4  | Multi-domain | MCI | CSF ATI+ | MoCA 8→12; MSQ 45→90 |
| 6) 65M  | 3/4  | Multi-domain | AD | CSF ATI+ | MoCA 19→26 |
| 7) 69M  | ND   | Amnestic, VS, calc | AD | MRI, CSF ATI+ | MoCA 15→27 |
| 8) 57M  | ND   | Amnestic, exec, VS | AD | CSF ATI+ | MoCA 26→37; MSQ 34→48 | Marked functional improvement |
| 9) 68F  | ND   | Amnestic, exec, calc, VS | AD | FDG-PET+ | MoCa 19→24; MSQ 16→4 |
| 10) 65M | 3/3  | Amnestic, VS | MCI | HC vol 9%ile | MoCA 20→92; MSQ 11→9 |
| 11) 66M | ND   | Amnestic, exec, VS | MCI | CSF ATI+ | MoCa 22→24 |
| 12) 60M | 3/4  | Amnestic, exec, VS | AD | MRI, NP | MoCA 17→21; MSQ 43→95 | Improved QOL |
| 13) 64F | ND   | Amnestic, exec, VS | AD | MRI | MoCA 20→24; MSQ 40→10 |
| 14) 77M | ND   | Amnestic, VS, calc | AD | MRI, CSF ATI+ | MoCa 24→26; MSQ 91→42 |
| 15) 64M | ND   | Amnestic, exec, calc, VS | AD | FDG-PET+ | MoCa 13→19 |
| 16) 50M | 3/3  | Amnestic, aphasis | SCI | MRI | MoCa 27→28; MSQ 88→97 |
| 17) 70M | ND   | Amnestic, exec, aphasis, VS | AD | FDG-PET+ | MoCa 19→24; MSQ 16→4 | Marked subjective improvement; cont’d high-level employment |
| 18) 60M | 3/4  | Amnestic, exec, VS | MCI | CSF ATI+ | MoCa 19→20 |
| 19) 57M | ND   | Severe multi-domain | AD | MRI, NP, CSF | MoCa 0→5; MSQ 36→16 |
| 20) 80M | 3/3  | Amnestic | SCI | MRI, CSF | MoCa 26→29; MSQ 25→4 |
| 21) 69M | ND   | Amnestic | MCI | MRI, CSF | MoCa 26→30; MSQ 31→20 |
| 22) 58F | 4/4  | Amnestic, exec, VS | AD | FDG-PET+ | MoCa 5→8; MSQ 14→98 |
| 23) 69M | ND   | Amnestic | AD | MRI | MoCa 19→26; MSQ 29→17 | Doing well at work |
| 24) 63F | ND   | Amnestic | AD | MRI | MoCa 23→27; MSQ 31→20 |
| 25) 71F | 3/3  | Amnestic, exec | AD | qEEG | MoCa 18→23; CNS-VS exec 1→63%ile; cog flex 1→58%ile; qEEG 25D increase beta power | Marked memory improvement; return to driving and independence |
| 26) 75M | ND   | Exec | MCI | qEEG | MoCa 21→29; qEEG normalized |
| 27) 67F | 3/4  | Amnestic, exec | AD | qEEG | MoCa 15→19 | Insomnia resolved |
| 28) 61F | ND   | Amnestic, exec | SCI | qEEG | CNS-VS SCI 40→73%ile; qEEG global beta power normalized | Marked subjective improvement |
| 29) 61F | 2/4  | Exec | MCI | qEEG | CNS-VS SCI 4→968%ile | Able to DC stimulant medication |
| 30) 71M | 3/3  | Amnestic, exec | SCI | qEEG | CNS-VS SCI 30→81%ile |
| 31) 63F | 4/4  | Amnestic, exec | AD | qEEG | MoCa 3→9 |
| 32) 78M | 3/3  | Amnestic, exec | AD | qEEG | MoCa 9→13 | Marked subjective improvement; regained dressing and independent bathroom use |
| 33) 50M | 3/4  | Amnestic, exec, calc | AD | Am-PET+, FDG-PET+ | MoCa 0→9 | Marked subjective improvement |
| 34) 71M | 2/3  | Amnestic | MCI | MRI | MoCa 24→29 |
| 35) 81F | 3/4  | Amnestic | AD | HC atrophy | MoCa 10→12 | Marked subjective improvement |
| 36) 78F | 4/4  | Amnestic | AD | HC volume <1%ile | MoCa 16→20 | Able to run his business |
| 37) 77M | 3/4  | Amnestic | AD | FDG-PET+ | MoCa 14→18 | Clear subjective improvement |
| 38) 65F | 3/4  | Amnestic | AD | MRI, PET | MoCa 21→24; stable 1.5y+ | Word recall markedly improved |
| 39) 70M | ND   | Amnestic | AD | FDG-PET+, CSF ATI+ | MoCa 19→27; MSQ 16→7 |
| 40) 54F | ND   | Amnestic | AD | MRI | MoCa 19→23; MSQ 44→41 |
| 41) 70F | 3/3  | Amnestic | SCI | CVLT 39→59%ile |
| 42) 79M | 3/4  | Amnestic | AD | SLUMS 14→18 |
| 43) 85M | 3/4  | Amnestic, exec | AD | SLUMS 17→22 |
| 44) 84M | 3/3  | Amnestic, exec | MCI | MRI | SLUMS 19→26 |
| 45) 79F | 3/3  | Amnestic | AD | MRI | MoCa 14→18 |
| 46) 65M | 4/4  | Amnestic, exec | MCI | MRI, PET | SLUMS 21→28 |
| 47) 68F | 3/3  | Amnestic | SCI | CVLT 18→26%ile |
| 48) 54M | 4/4  | Amnestic | SCI | CVLT 54→96%ile |
| 49) 77F | 4/4  | Amnestic | MCI | MRI | MoCa 23→25; MSQ 17→7 |

Citation: Bredesen DE, Sharlin K, Jenkins D, Okuno M, Youngberg W, et al. (2018) Reversal of Cognitive Decline: 100 Patients. J Alzheimers Dis Parkinsonism 8: 450. doi: 10.4172/2161-0460.1000450
50) 64M 3/3 Amnestic, exec AD SLUMS 15→20
51) 58F 3/3 Amnestic, exec AD CT: Cerebral atrophy CNS- VS memory 1→27%ile Marked subjective improvement
52) 70M 3/4 Amnestic AD MoCA 18→21
53) 62M 3/4 Amnestic, calc MCI MRI NP on-line 36→53%ile Marked subjective improvement
54) 58F 3/3 Exec, calc MCI NP CNS- VS 23→95%ile
55) 77M 3/4 Amnestic AD CT: cerebral atrophy CNS- VS 33→95%ile Returned independence
56) 68F 4/4 Amnestic AD Cerebral atrophy CNS- VS 1→14%ile
57) 72M 4/4 Amnestic MCI HC vol <5%ile CNS- VS 7→12%ile
58) 77M 3/4 Amnestic MCI MoCA 23→25
59) 63M 3/3 Amnestic AD Am-PET+ MMSE 24→28
60) 64M 4/4 Amnestic AD HC atrophy MMSE 22→29
61) 71M 3/4 Aphasic, exec AD MRI MoCA 5→9 Declined Vastly improved, converting again, dressing himself, calling grandchildren by name, working again
62) 73F 3/4 Amnestic AD qEEG, evoked potentials MoCA 9→20; AQ21 20→8; P300 lat. 608→576; P300s amp. 13→15.6
63) 62F ND Amnestic MCI/ AD MoCA 20→28 Patient 3 (above)
64) 73M 4/4 Amnestic MCI MoCA 25→30
65) 69F 3/4 Amnestic, exec AD MoCA 16→19 Minimal speech→fluid normal speech
66) 58M 3/4 Amnestic MCI MRI; HC vol 12%ile MoCA 26→28; HC vol 12→24%ile Rapid decline prior to treatment
67) 70F 3/3 Amnestic MCI CNS- VS NCI 32→96%ile; psych speed 13→68%ile
68) 91M ND Exec AD MMSE 22→27
69) 76F 3/3 Amnestic, exec AD MRI; HC vol 47%ile MoCA 17→25 Returned ability to read
70) 69M 3/3 Amnestic, calc AD Am-PET+ MoCA 15→25
71) 80M 3/3 Amnestic AD FDG-PET+ Memory score ↑15% Able to DC anti-hyp., statin; glucose improved
72) 64M 4/4 Amnestic, exec AD MRI: HC vol 10%ile, gen. atrophy MoCA 20→24
73) 75M 3/4 Amnestic, exec, VS AD MRI: HC vol 12%ile MoCA 6→9 Declined off protocol, improved back on
74) 62M ND Amnestic, exec AD MMSE 20→24 Improved writing and map following
75) 76M 3/3 Amnestic AD MRI MoCA 20→22 Improved memory
76) 50M 3/3 Exec AD FDG-PET+ MMSE 23→27 Marked subjective improvement
77) 53F 3/3 Exec, calc AD Am-PET+ MoCA 10→16
78) 50F 2/4 Amnestic MCI NP NP normalized, prosop. cleared, word finding improved Regained ability to play piano; sustained improvement 3y ongoing; fu of pt. reported previously [4]
79) 68F 2/4 Amnestic, exec MCI MoCA 25→29 Memory, driving directions much improved
80) 80F 3/3 Amnestic, exec AD MoCA 18→24 Memory much improved
81) 61F 3/3 Exec AD FDG-PET: temp hypometab NCI 33→79%ile; exec 1→77%ile; cog flex 1→77%ile Marked subjective improvement
82) 54F 3/3 Amnestic, exec AD FDG-PET+ MoCA 19→21 Reading, navigating again; earlier fu reported [4]
83) 78F 3/4 Amnestic, exec, praxis AD MRI: HC vol <1%ile MoCA 0→3 Striking change: speaking, dressing, dancing, biking, emailing, kayaking all returned
84) 74M 3/4 Amnestic AD FDG-PET+ CVLT-II B 3→84%ile Improvement sustained at 4.5 yr; fu to initial report [4]
85) 69F 3/4 Exec AD MRI: cerebral atrophy MoCA 18→27 Driver’s license returned; follows recipes again; nurse asked, “What happened?”
86) 68M 3/4 Amnestic MCI Am-PET+; FDG-PET+ HC vol 17→75%ile Sustained improvement 4yr; fu to initial report [4]
87) 65M 3/3 Amnestic, exec, calc MCI FDG-PET+ Improved math, memory, able to play poker at high level again
88) 54F 4/4 Amnestic MCI NP: cog assessment 35→98%ile Sustained improvement 6yr; fu to [4]
89) 57F 4/4 Amnestic MCI NP NCI 16→93%ile Sustained improvement 2y; fu to [4]
90) 76M 4/4 Amnestic AD FDG-PET+ MMSE 23→30 Declined when DC’d protocol, improved back on, fu to [4]
Discussion

Alzheimer's disease represents a major healthcare problem, and the failure to develop effective treatment and prevention for Alzheimer's would have dire consequences nationally and globally, the bankruptcy of Medicare being among them. Therefore, the development of effective treatments is a high priority for translational biomedicine and public health programs throughout the world. However, the area of neurodegenerative diseases is arguably the area of greatest biomedical therapeutic failure from Alzheimer's to Parkinson's to Lewy body disease to amyotrophic lateral sclerosis to frontotemporal dementia to progressive supranuclear paralysis to macular degeneration and other degenerative diseases, there has been no effective treatment with a sustainable, disease-modifying effect.

There may be several reasons for such uniform failure: attempting to treat without identifying the cause(s) and contributors for each patient may be one reason. Assuming a single cause, attempting to treat with a monotherapy, uniform and monophasic, may all contribute to previous suboptimal and ineffective approaches. Furthermore, targeting the mediators (e.g., Aβ peptides) instead of the root causes (e.g., pathogens, toxins, and insulin resistance) may be yet another reason for the lack of success to date.

Here we have taken a very different approach, evaluating and addressing the many potential contributors to cognitive decline for each patient. This has led to unprecedented improvements in cognition. Most importantly, the improvement is typically sustained unless the protocol is discontinued, and even the initial patients treated in 2012. Since the evaluations in those cases did not provide definitive evidence of Alzheimer's, nor did they provide definitive evidence of any other specific degenerative condition. The patients shown to improve included some whose laboratory values suggested each of the major subtypes [3,5].

The results presented here were obtained by multiple physicians at multiple sites, suggesting that the approach should be scalable and practicable for many physicians. These results should also provide background to support randomized, controlled, prospective clinical trials. Gaining approval for such trials may be difficult, however, since they will necessarily be multi-variable and non-uniform (i.e., personalized). Furthermore, it is highly unlikely that the therapeutic response will act as a linear system, and thus the effect of the program as a whole is unlikely to equal the sum of the effects of each component, making the dissection of the protocol components difficult. However, alternative approaches such as the removal of single components systematically, or the comparison of large numbers of program effects differing by a few components, may offer some insight into the most important components (although of course these may vary from patient to patient).

In the current set of 100 patients, for those evaluated by MoCA, MMSE, or SLUMS pre- and post-treatment (72 of the 100), there was a mean improvement of 4.9 points, with a standard deviation of 2.6 and a range of 1-12. Since the natural history is one of decline, the improvements that were documented must be considered as additional to the prevention of decline that would otherwise have occurred. Of course these numbers must be tempered with any failures that occur, so that it will be important to revise these in the context of a randomized, controlled clinical trial.

One of the benefits of the protocol used here is that it may enhance pharmaceutical testing and clinical trials: given the lack of improvement in the vast majority of monotherapy trials, it is possible that one problem results from a floor effect, i.e., there may be a threshold.
effect needed to measure improvement. However, the positive effects described here might conceivably place the patients in a dynamic range in many cases, such that smaller effects both positive and negative might be detectable.

As more patients are treated with this approach, patterns of improvement vs. lack of improvement, timing, which domains typically improve and which do not, and related insights are likely to emerge. Although this was not a focus of the cases reported here, certain observations were made repeatedly. One of these was that the significant others of the patients typically reported that the patients were “more engaged” and more responsive with treatment. Facial recognition, navigation, and memory were often improved, whereas calculation and aphasia were less often improved. For those in whom specific pathogens or toxins were identified, either improvement did not occur until those were targeted therapeutically, or further improvement occurred when they were targeted. Not surprisingly, those patients showing less decline at the time of initiation of treatment responded more readily and completely than those who were further along in the course of the illness. However, there were examples of improvement even with MoCA scores as low as zero.

In summary, a targeted, personalized, precision medicine approach that addresses the multiple potential contributors to cognitive decline for each patient shows promise for the treatment of Alzheimer’s disease and its harbingers, MCI and SCI. The improvements documented in the 100 patients reported here provide support for the performance of a prospective, randomized, controlled clinical trial, especially given the current lack of effective treatment for this common and otherwise terminal illness.

Acknowledgment

We are grateful to the many practitioners evaluating and treating patients with cognitive decline, using this comprehensive protocol. We are especially grateful to Dr. Mary Kay Ross, Hilary Shafto, and Margaret Conger for seeing some of the patients reported here, to Dr. Kristine Lokken, Dr. Jonathan Canick, and Dr. Katayoon Shahrokh Walters for some of the neuropsychological evaluations, to Amanda Williams and Cytoplan Ltd. for providing some of the supplements for some patients, to James and Phyllis Easton for critical research support, and to the Evanthea Foundation for support in preparation of a clinical trial.

References

1. Bredesen DE (2014) Reversal of cognitive decline: A novel therapeutic program. Aging 6: 707-717.
2. Bredesen DE, Amos EC, Canick J, Ackerley M, Raji C, et al. (2016) Reversal of cognitive decline in Alzheimer’s disease. Aging 8: 1250-1258.
3. Bredesen DE (2015) Metabolic profiling distinguishes three subtypes of Alzheimer’s disease. Aging 7: 595-600.
4. Bredesen DE (2016) Inhalational Alzheimer’s disease: An unrecognized - and treatable - epidemic. Aging 8: 304-313.
5. Bredesen DE (2017) The end of Alzheimer's: The first program to prevent and reverse cognitive decline. (1stedn), Avery, an imprint of Penguin Random House, New York.
6. James BD, Leurgans SE, Hebert LE, Scherr PA, Yaffe K, et al. (2014) Contribution of Alzheimer disease to mortality in the United States. Neurology 82: 1045-1050.
7. Bredesen DE, John V (2013) Next generation therapeutics for Alzheimer’s Disease. EMBO Mol Med 5: 795-798.
8. Rabizadeh S, Oh J, Zhong LT, Yang J, Bittler CM, et al. (1993) Induction of apoptosis by the low-affinity NGF receptor. Science 261: 345-348.
9. Mehlen P, Rabizadeh S, Snipas SJ, Assa-Munt N, Salvesen GS, et al. (1998) The DCC gene product induces apoptosis by a mechanism requiring receptor proteolysis. Nature 395: 801-814.
10. Bredesen DE, Mehlen P, Rabizadeh S (2004) Apoptosis and dependence receptors: A molecular basis for cellular addiction. Physiol Rev 84: 411-430.
11. Soscia SJ, Kirby JE, Washicosky KJ, Tucker SM, Ingelsson M, et al. (2010) The Alzheimer’s disease-associated amyloid beta-protein is an antimicrobial peptide. PLoS One 5: e9505.